Introducing an extraordinary innovation harnessing the potential of phytogenics, phycogenics, and organic acids, fortified with a dual encapsulation structure. This state-of-the-art solution combines safety and efficacy in the endeavor to mitigate Salmonella in poultry farms. The dual encapsulation design ensures that the active constituents are only released upon reaching the bird’s intestines, guaranteeing maximum impact.
R&D Director
NUQO
Salmonella, a bacterial infection that poses a threat to both humans and animals, is a significant worry in broiler chicken production. The presence of Salmonella can lead to food contamination and the potential for foodborne diseases. As a result, it is essential to implement robust biosecurity procedures to thwart Salmonella contamination. Emerging technologies provide promising approaches to preventing Salmonella by focusing on the pathogen within the digestive systems of the birds. By combining rigorous biosecurity protocols with the application of effective feed additives, broiler producers can guarantee the production of safe, high-quality broilers while concurrently lowering the risk of Salmonella infection.
A DOUBLE-ENCAPSULATION TECHNOLOGY FOR SPECIFIC PATHOGENS
Recently, a biotech company developed a new technology, based on an exclusive formulation and a new double encapsulation approach (NUQO©SAFE). The company worked on one advanced concept: a double micro-encapsulation with one layer made of phytogenics and phycogenics (active molecules from plants and algae) and one inner core containing multiple organic acids. The new product enables an accurate and precise controlled released of ingredients in the gut; active compounds are released specifically between the duodenum up to the colon, with a sequenced release of the different ingredients, so that every compound gets released on spot to enhance digestive functions and control gut microflora.
HIGH EFFICACY IN REDUCING SALMONELLA COLONIZATION
Multiple trials have confirmed a positive effect. One recent trial was performed at Ridgeway Research in UK. Ross 308 female day-old chicks were brought into the facility on day 0, weighted and randomly allocated to different treatments. At day 14, all chicks were inoculated with 0,1 ml containing 1 x 108 CFU of Salmonella enteritidis suspension. The animals were separated in 2 groups: One control group (NC) and one group fed with this new technology (NQ) at 400 g/t.
(measured in cloacal swabs)
Prior to infection, no birds were infected with Salmonella. Post-infection, 63% and 38% of the birds in the NC group were infected at day 21 and day 35, respectively. The number of Salmonella positive samples was reduced by half at both time points for the animals from the NQ group. From the birds that were positive at day 21, one part naturally recovered from the infection (“previously positive”). The recovery rate is similar in both treatment group (~60%). From the birds positive at day 35, a part was already positive at day 21 and a part turned positive between day 21 and day 35 (“new positive”). The NQ group had much less ‘new positive’ than the NC group, which indicates a stronger support against Salmonella, not only shortly after the infection but during the whole production cycle. Overall, there were fewer birds ever infected with Salmonella for the NQ group (33% total infection rate vs 75%) and, at day 35, there were much fewer positive birds in the NQ group than in the control (16% vs 38%).
In parallel, scientists measured the immune response via the concentration of Salmonella IgA in blood. Prior to infection, the base level of IgA was around 15ng/ml in both treatment groups. At day 21, the blood IgA concentration increased to about 40 ng/ml in the NC group, showing the immune response of the birds to the Salmonella infection. Birds from the NQ group had 11% more blood IgA at day 21 than birds from the NC group, which indicates a better immune response. Finally, scientists measured the impact of both treatments on performance. The birds from the NQ group had a 1-point improvement in feed conversion ratio, which shows the effects of some of its components on digestibility and gut integrity.
SWIFT INTEGRATION OF CUTTING-EDGE TECHNOLOGY: BENEFITS AND TESTIMONIALS
This cutting-edge technology is rapidly gaining traction in the market and attracting a wide range of new customers. Among these customers, one has been incorporating NUQO©SAFE into their existing product portfolio since 2022 and offers their testimony: “Initial results have indicated a favorable response on the farms that have adopted this product. Starting in December 2022, all newly introduced flocks have been receiving NUQO©SAFE as part of their dietary regimen.”
Furthermore, the technical manager involved in this initiative has commented on the positive outcomes, noting that the birds settle more quickly after being transferred from rearing farms, display excellent early body condition, achieve improved production yields, can reduce feed specifications without increasing daily intake, and exhibit increased vigor and vitality. This customer is implementing the technology on a large scale to ensure consistent high performance and promote optimal gut health.
DISCOVER AN EXCLUSIVE BREAKTHROUGH: ADVANCED TECHNOLOGY FOR SALMONELLA CONTROL IN POULTRY FARMING
Introducing an extraordinary innovation harnessing the potential of phytogenics, phycogenics, and organic acids, fortified with a dual encapsulation structure. This state-of-the-art solution combines safety and efficacy in the endeavor to mitigate Salmonella in poultry farms. The dual encapsulation design ensures that the active constituents are only released upon reaching the bird’s intestines, guaranteeing maximum impact. This exceptional technology is precisely tailored to directly combat the pathogen while reinforcing the bird’s innate immune response. By significantly lowering the risk of Salmonella infection, this groundbreaking solution not only enhances the overall health of your poultry but also plays a crucial role in averting food contamination and foodborne illnesses. Embrace this innovation to promote a healthier flock and ensure the safety of poultry products.
About Dr Stephanie Ladirat
Dr Stephanie Ladirat is the technology director at NUQO. She obtained her MSc degree in Food Technology with a specialization in Food Ingredient and Functionality and her PhD degree in Food Chemistry from Wageningen University (The Netherlands). During her PhD thesis, she studied in depth the human gut microbiota composition and its modulation upon prebiotic supplementation and/or antibiotic treatments. From 2014 till 2020, she worked at Cargill Animal Nutrition, first as technology lead for gut health additives and, then, as swine portfolio manager. She provided global technical product support for a broad range of products (phytogenics, organic acids, short and medium chain fatty acids, probiotics) and trained technical and sales teams. She most recently managed R&D projects and developed innovative feed additive solutions to answer specific customer needs related to animal gut health and performance.
